The Boston-based venture firm Oxford Bioscience Partners has held the first $66 million close of its sixth fund, Dan Primack of Fortune writes today. During his Thomson Reuters days, Primack caused a stir at Oxford when he wrote an obituary of sorts on the venture firm along with other VCs that he believed were no longer making new investments. Today, he writes that Oxford, a life sciences-focused firm, has raised the first part of its new fund from the government of South Korea and the city government of Seoul.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
